Evidence map›Paper›PMID 22820275›Full record

ArticleNeuropharmacology2013

Atomoxetine modulates spontaneous and sensory-evoked discharge of locus coeruleus noradrenergic neurons.

A Bari, G Aston-Jones

Open access · greenAbstract read
In one paragraph

Article in Neuropharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 91 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Review
  11. Article
  12. Neurotransmitter Systems in Alzheimer's Disease.Current issues in molecular biology · 2026
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Elevated and accelerated: Locus coeruleus activity and visual search abilities in autistic children.Cortex; a journal devoted to the study of the nervous system and behavior · 2023
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

A BariDepartment of Neurosciences, Medical University of South Carolina, 173 Ashley Ave, BSB 409, Charleston, SC 29425, USA. bari@musc.edu
G Aston-Jones
Medical University of South Carolina · US

Funding

Role of Extended Amygdala in Opiate and Cocaine AbuseR37DA006214 · NIDA · UNIVERSITY OF PENNSYLVANIA · PI ASTON-JONES, GARY S. · 2003 to 2012
$4.2M
Role of Locus Coeruleus in Response InhibitionR01MH092868 · NIMH · RBHS-ROBERT WOOD JOHNSON MEDICAL SCHOOL · PI ASTON-JONES, GARY S. · 2011 to 2015
$1.8M
NIDA NIH HHS R37 DA006214NIDA NIH HHS R37-DA06214NIMH NIH HHS R01 MH092868NIMH NIH HHS R01-MH MH092868
6 · The paper itself

Abstract

Atomoxetine (ATM) is a potent norepinephrine (NE) uptake inhibitor and increases both NE and dopamine synaptic levels in prefrontal cortex, where it is thought to exert its beneficial effects on attention and impulsivity. At the behavioral level, ATM has been shown to cause improvements on the measures of executive functions, such as response inhibition, working memory and attentional set shifting across different species. However, the exact mechanism of action for ATM's effects on cognition is still not clear. One possible target for the cognitive enhancing effects of ATM is the noradrenergic locus coeruleus (LC), the only source of NE to key forebrain areas such as cerebral cortex and hippocampus. Although it is known that ATM increases NE availability overall by blocking reuptake of NE, the effects of this agent on impulse activity of LC neurons have not been reported. Here, the effect of ATM (0.1-1 mg/kg, ip) on NE-LC neurons was investigated by recording extracellular activity of LC neurons in isoflurane-anesthetized rats. ATM caused a significant decrease of the tonic activity of LC single-units, although leaving intact the sensory-evoked excitatory component of LC phasic response. Moreover, the magnitude of the inhibitory component of LC response to paw stimulation was increased after 1 mg/kg of ATM and its duration was prolonged at 0.3 mg/kg. Together, these effects of ATM produced an increase in the phasic-to-tonic ratio of LC phasic response to sensory stimulation. ATM also modulated the average sensory-evoked local field potential (LFP) and spike-field coherence in LC depending on the dose tested. The lower dose (0.1 mg/kg) significantly decreased early positive and negative components of the sensory-evoked LFP response. Higher doses (0.3-1 mg/kg) initially increased and then decreased the amplitude of components of the evoked fields, whereas the spike-field coherence was enhanced by 1 mg/kg ATM across frequency bands. Finally, coherence between LC fields and EEG signals was generally increased by 1 mg/kg ATM, whereas 0.1 and 0.3 mg/kg respectively decreased and increased coherence values in specific frequency bands. Taken together these results suggest that ATM effects on LC neuronal activity are dose-dependent, with different doses affecting different aspects of LC firing. This modulation of activity of LC-NE neurons may play a role in the cognitive effects of ATM. This article is part of a Special Issue entitled 'Cognitive Enhancers'.

Indexed as

Adrenergic NeuronsAdrenergic Uptake InhibitorsAnimalsAtomoxetine HydrochlorideDose-Response Relationship, DrugElectroencephalographyElectroencephalography Phase SynchronizationEvoked PotentialsEvoked Potentials, SomatosensoryInjections, IntraperitonealLocus CoeruleusMaleNeural InhibitionNootropic AgentsPropylaminesRandom AllocationAdrenergic Uptake InhibitorsAtomoxetine HydrochlorideNootropic AgentsPropylamines

Identifiers

PMID22820275
PMCPMC3445720
OpenAlexW2161753804

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.